Core Viewpoint - The implementation of new policies in 2024 has led to a significant increase in cash dividends among listed companies in China's stock markets, indicating a positive trend in shareholder returns and market stability [1] Summary by Sections Dividend Trends - In 2024, a total of 3,755 listed companies in the Shanghai and Shenzhen stock exchanges implemented cash dividends, with a total cash dividend amount of approximately 2.4 trillion yuan, marking an increase of 11.7% in the number of dividend-paying companies and a 14.7% increase in total dividend amount compared to 2023 [1] High Dividend Payouts - Some companies are engaging in "clearance-style dividends," where they distribute nearly all of their annual net profits as dividends. This practice raises concerns about the sustainability of the companies' future development and the efficiency of capital market resource allocation [1] Case Study: Chengda Bio - Chengda Bio reported a revenue of 1.676 billion yuan in 2024, a decrease of 4.22% year-on-year, and a net profit of 343 million yuan, down 26.42% year-on-year. The company has seen a continuous decline in revenue and net profit for three consecutive years since its listing [2] - Despite declining performance, Chengda Bio distributed a total cash dividend of 329 million yuan in 2024, with a dividend payout ratio of 96.06%. The largest shareholder, Liaoning Chengda Co., Ltd., holds 54.67% of the company's shares, indicating that a significant portion of the dividends benefits the major shareholder [2] Risks of High Dividend Strategies - The "clearance-style dividend" strategy, while appearing to provide substantial returns to shareholders, poses multiple risks. Distributing nearly all or exceeding the current net profit undermines the company's future development and risk reserves [3] - The practice of using excess funds from IPOs for dividends distorts the capital market's resource allocation function, as these funds should ideally support the company's growth rather than serve as a means for major shareholders to cash out [3] - High dividend payouts in companies with declining fundamentals raise questions about the fairness and rationality of such actions, potentially harming the long-term interests of minority shareholders and the company as a whole [3]

原标题："成大生物：董丙建、崔建伟辞去公司董事职务" 每经AI快讯，成大生物（SH 688739）8月12日晚间发布公告称，因工作需要，董丙建先生申请辞去公 司董事及董事会战略委员会委员职务，辞职后将不再担任公司任何职务。崔建伟先生申请辞去公司董事 职务。辞职后将不再担任公司任何职务；崔建伟先生申请辞去公司董事职务，辞职后仍将担任公司副总 经理、财务总监职务。根据公司控股股东辽宁成大股份有限公司推荐、经董事会提名委员会资格审查通 过，董事会同意提名徐飚先生、周岳先生为公司第五届董事会非独立董事候选人。保证董事会专门委员 会能够顺利高效开展，在公司股东会审议通过选举徐飚先生为公司董事之日起，选举徐飚先生为公司第 五届董事会战略委员会委员。 截至发稿，成大生物市值为120亿元。 延伸阅读： 天成自控:徐华月辞去公司财务总监职务 东方通信聘任王妍为公司财务总监 广东明珠:聘任凌炜担任公司财务总监 2024年1至12月份，成大生物的营业收入构成为：生物制药占比100.0%。 ...

证券代码：688739 证券简称：成大生物 公告编号：2025-039 辽宁成大生物股份有限公司 第五届董事会第二十一次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 辽宁成大生物股份有限公司（以下简称"公司"）第五届董事会第二十一次会议 通知已于 2025 年 8 月 8 日以电子邮件方式发出，会议于 2025 年 8 月 12 日以现场和 通讯相结合的方式召开并作出决议。公司应出席会议的董事 7 人，实际出席会议的董 事 7 人，会议由董事长李宁先生主持。本次会议的召集、召开和表决情况符合《中华 人民共和国公司法》（以下简称"《公司法》"）等法律法规及《公司章程》的规定， 形成的决议合法有效。 二、董事会会议审议情况 （一）审议通过《关于补选公司董事的议案》 公司董事会于近日收到董事董丙建先生与董事崔建伟先生的书面辞职报告。为完 善公司治理，保证公司董事会的规范运作，根据《公司法》《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》《公司章程》等相关规定，依据公司控 ...

证券代码：688739 证券简称：成大生物 公告编号：2025-041 辽宁成大生物股份有限公司 关于公司董事变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 辽宁成大生物股份有限公司（以下简称"成大生物"或"公司"）董事会于 近日收到董事董丙建先生与崔建伟先生的书面辞职报告。因工作需要，董丙建先 生申请辞去公司董事及董事会战略委员会委员职务，辞职后将不再担任公司任何 职务；崔建伟先生申请辞去公司董事职务，辞职后仍将担任公司副总经理、财务 总监职务。根据公司控股股东辽宁成大股份有限公司推荐、经董事会提名委员会 资格审查通过，董事会同意提名徐飚先生、周岳先生为公司第五届董事会非独立 董事候选人，任期自公司股东会审议通过之日起至第五届董事会届满之日止。该 议案尚需提交公司股东会审议。 公司于 2025 年 8 月 12 日召开第五届董事会第二十一次会议，审议通过了 《关 于补选公司董事的议案》。根据公司控股股东辽宁成大股份有限公司推荐、经董 事会提名委员会资格审查通过，董事会提名徐飚先生、周岳先生为公司第 ...

辽宁成大生物股份有限公司 信息披露管理制度 辽宁成大生物股份有限公司 信息披露管理制度 第一章 总 则 第一条 为提高辽宁成大生物股份有限公司（以下简称"公司"）信息披露工作质 量和规范信息披露行为，确保公司对外信息披露工作的真实性、准确性、及时性，保 护公司、股东、债权人及其他利益相关者的合法权益，根据《中华人民共和国公司法》 （以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司信息披露管理办法》（以下简称"《管理办法》"）《上海证券交易所科 创板股票上市规则》（以下简称"《上市规则》"）及其他有关法律、法规、规范性 文件和《辽宁成大生物股份有限公司章程》（以下简称"《公司章程》"）的规定， 制定本制度。 第二条 本制度所称"信息披露"是指公司将对公司股票及其衍生品种交易价格可 能产生较大影响而投资者尚未得知的信息或影响投资者作出价值判断和投资决策的重 大信息，在规定的期限内，通过上海证券交易所网站和符合中国证监会规定条件的媒 体，以规定的方式向社会公众公布，并按照规定报送证券监管部门。 第三条 本制度适用于如下人员和机构： (一) 公司董事会秘书和信息披露事务管理部门； ...

General Principles - The purpose of the independent director system is to enhance the corporate governance structure of Liaoning Chengda Biological Co., Ltd. and create a favorable working environment for independent directors [1][2] - Independent directors are defined as those who do not hold any other positions in the company and have no direct or indirect interests that could hinder their independent judgment [1][2] Independent Director Responsibilities - Independent directors have a duty of loyalty and diligence to the company and all shareholders, and they must perform their duties in accordance with relevant laws and the company's articles of association [1][2] - They are required to participate in decision-making, supervision, and provide professional advice to protect the overall interests of the company and the legal rights of minority shareholders [1][2] Qualifications and Independence - Independent directors must meet specific qualifications, including having at least five years of relevant work experience and a good personal character without significant credit issues [2][3] - The company must ensure that independent directors maintain their independence and are not influenced by major shareholders or actual controllers [2][3] Nomination and Election - Independent directors can be nominated by the board of directors or shareholders holding more than 1% of the company's issued shares, and their qualifications must be reviewed before nomination [5][6] - The election of independent directors must be conducted separately from non-independent directors, and cumulative voting is required when electing multiple independent directors [6][14] Duties and Powers - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing objective advice to enhance decision-making quality [18][19] - They have special powers, including the ability to hire external consultants, propose meetings, and express independent opinions on matters that may harm the company or minority shareholders [19][20] Communication and Reporting - The company must establish a communication mechanism between independent directors and minority shareholders, allowing independent directors to verify investor inquiries [29] - Independent directors are required to submit annual reports on their performance to the company's annual general meeting [30] Support and Compensation - The company must provide necessary working conditions and support for independent directors to fulfill their responsibilities [32][33] - Independent directors are entitled to compensation that corresponds to their responsibilities, which must be approved by the shareholders' meeting and disclosed in the annual report [38]

Core Points - The company aims to enhance communication with investors and potential investors, ensuring their rights and interests are protected while improving corporate governance and overall value [1][2][3] Group 1: Investor Relations Management Objectives - The primary objectives of investor relations management include fostering a positive relationship with investors, establishing a stable investor base, and promoting a culture that respects and serves investors [6][7] - The management aims to maximize overall corporate interests and shareholder wealth while increasing transparency in information disclosure and improving corporate governance [3][4] Group 2: Principles of Investor Relations Management - The management of investor relations must adhere to compliance, equality, proactivity, and integrity principles, ensuring fair treatment of all investors, especially minority shareholders [3][4][5] - The company must actively engage with investors, listen to their feedback, and respond to their requests in a timely manner [4][5] Group 3: Communication Channels and Methods - The company is required to establish multiple channels for communication, including the company website, new media platforms, and direct interactions such as meetings and roadshows [10][11] - It is essential to provide convenient access for investors to participate in communications and to promptly address any barriers to effective communication [10][11] Group 4: Information Disclosure and Transparency - The company must ensure that all disclosed information is accurate, complete, and easily understandable, avoiding any misleading statements or omissions [18][19] - Investor relations activities should not involve the release of undisclosed significant information or predictions regarding stock prices [6][7] Group 5: Responsibilities and Training - The board secretary is responsible for organizing and coordinating investor relations management, ensuring effective communication and handling of investor inquiries [29][30] - Regular training for directors and senior management on investor relations management is necessary to maintain compliance and effective communication [30][31] Group 6: Documentation and Record Keeping - The company must maintain comprehensive records of investor relations activities, including meetings, disclosures, and communications, ensuring all documentation is complete and accurate [36][37] - A dedicated team should be responsible for archiving both physical and electronic records related to investor relations [37]

Core Viewpoint - The document outlines the fundraising management system of Liaoning Chengda Biological Co., Ltd., emphasizing the proper use and management of raised funds to enhance efficiency and protect investors' rights [1]. Group 1: Fundraising Purpose and Management - The funds raised must be used specifically for designated purposes, primarily in line with national industrial policies and sustainable development principles, focusing on enhancing the company's competitiveness and innovation capabilities [2]. - The board of directors and senior management are responsible for ensuring the proper use of raised funds and must not engage in any unauthorized changes to their intended use [2][3]. - The company must disclose the usage of raised funds in accordance with relevant laws and regulations [3]. Group 2: Fund Storage and Supervision - Upon receipt of the raised funds, the company must establish a special account for centralized management and usage, ensuring that no non-fund-related transactions occur in this account [4][5]. - A tripartite supervision agreement must be signed with the sponsoring institution or independent financial advisor and the commercial bank holding the funds, detailing the management and oversight of the funds [5][6]. Group 3: Fund Usage Approval Process - The approval process for using raised funds involves multiple levels of management, requiring detailed records of fund inflows and outflows [6][7]. - The company must adhere to the usage plan outlined in the issuance application documents and disclose any significant deviations from this plan [7][8]. Group 4: Management of Idle Funds - Idle funds may be temporarily used for cash management, provided that such management does not affect the normal progress of investment plans [9][10]. - The company can use idle funds to supplement working capital, but this must be approved by the board and disclosed accordingly [10][11]. Group 5: Changes in Fund Usage - Any changes in the intended use of raised funds must be approved by the board and disclosed, ensuring that new projects align with the company's main business [12][13]. - The company must conduct feasibility analyses for new projects and ensure that they enhance competitiveness and innovation [13][14]. Group 6: Accountability and Reporting - The company is required to maintain accurate records of fund usage and report on the actual use of raised funds, including any discrepancies from planned usage [15][16]. - The board must regularly review the management and usage of raised funds and disclose findings in a special report [15].

Core Viewpoint - The document outlines the management measures for the shareholding changes of directors and senior management at Liaoning Chengda Biological Co., Ltd, emphasizing compliance with relevant laws and regulations to prevent insider trading and ensure transparency in share transactions [1][2]. General Principles and Regulations - The management measures apply to all shares held by directors and senior management, including those held in multiple accounts and through margin trading [2]. - Senior management includes positions such as the general manager, deputy general managers, board secretary, and financial director [2]. - Directors and senior management must be aware of legal prohibitions against insider trading and market manipulation before engaging in share transactions [2]. Transfer of Shares - Directors and senior management can transfer a maximum of 25% of their total shares annually, with exceptions for judicial enforcement or inheritance [3]. - Shares held by directors and senior management that increase during the year will be included in the calculation of transferable shares for that year [3]. - Untransferred shares at the end of the year will be counted towards the next year's transferable shares [3]. Restrictions on Share Transactions - Directors and senior management are prohibited from transferring shares within six months after leaving their positions [10]. - They cannot engage in share transactions during specific periods, such as before the announcement of annual or quarterly reports [6][7]. - There are strict rules against transferring shares if the company is under investigation for securities violations or if the individual is under investigation for related offenses [5][10]. Notification and Disclosure - The board secretary is responsible for managing the data and information related to the shareholdings of directors and senior management [8]. - Any plans for buying or selling shares must be communicated in writing to the board secretary for confirmation [8]. - Directors and senior management must report any changes in their shareholdings within two trading days [9]. Accountability - The board of directors is responsible for addressing violations of these management measures [11]. - Any illegal trading activities by directors and senior management may result in their dismissal and potential civil liability for damages caused to the company [11][12]. - Profits from violations of these regulations must be returned to the company [11].

Core Viewpoint - The document outlines the external guarantee management system of Liaoning Chengda Biological Co., Ltd., aiming to standardize external guarantee behaviors and effectively prevent related risks [1][2]. Chapter Summaries Chapter 1: General Principles - The system is established based on various laws and regulations to regulate the company's external guarantee behavior [1]. Chapter 2: Guarantee Principles - External guarantees refer to the company and its subsidiaries providing guarantees based on legal agreements, adhering to principles of fairness, voluntariness, and mutual benefit [2]. - The scope of this system includes the company and its subsidiaries [1]. Chapter 3: Guarantee Approval Management - All guarantees must be managed centrally by the company, requiring approval from the board of directors or shareholders before any guarantee is provided [2][3]. - Guarantees for related parties must have reasonable commercial logic and require disclosure and shareholder approval [2]. Chapter 4: Contract Signing - After board or shareholder approval, the chairman or other senior management is authorized to sign guarantee contracts [4][6]. - Guarantee contracts must comply with legal norms and clearly define the terms [6]. Chapter 5: Guarantee Risk Management - The board and finance department are responsible for managing and reviewing guarantee behaviors [7]. - Any abnormal contracts not approved by the board must be reported immediately [7]. Chapter 6: Accountability - Directors and managers who violate the established procedures for signing guarantee contracts may face economic and legal consequences [8]. - Individuals who fail to perform their duties, causing losses to the company, may be subject to penalties [8]. Chapter 7: Supplementary Provisions - Any matters not covered by this system or conflicting with legal requirements will be executed according to relevant laws and regulations [8].